4 Results for "

Ocular metabolism

" in MedChemExpress (MCE) Product Catalog:
Products (4)

4 Results for "Ocular metabolism" in MCE Product Catalog:

Cat. No.: HY-17569
CAS No.: 23674-86-4
Target:  

Phospholipase

Research Areas:  

Inflammation/Immunology

Difluprednate is a glucocorticoid receptor (GC receptor) agonist with a Ki of 0.78 nM. Difluprednate's active metabolite 21-deacetylated difluprednate (DFB) is a competitive agonist of GC receptors with a Ki of 0.061 nM. Difluprednate binds to GC receptors through metabolism to DFB, regulating the transcription of inflammatory mediator genes, thereby exerting anti-inflammatory activity. Difluprednate can be used for research related to ocular inflammation, such as postoperative inflammation, anterior uveitis, etc .
loading...
    loading...
Cat. No.: HY-187671
CAS No.: 59756-39-7
Enolicam sodium is a dual inhibitor of cyclooxygenase (COX) and lipoxygenase (LOX), with a COX IC50 of 1.5 μM and a 5-LOX IC50 of 3.5 μM. Enolicam sodium inhibits arachidonic acid metabolism via the COX and 5-LOX pathways. Enolicam sodium inhibits the production of reactive oxygen species (ROS), superoxide anions, hydrogen peroxide, and the release of polymorphonuclear leukocytes. Enolicam sodium is applicable to research related to acute oxidative lung injury and ocular inflammation .
loading...
    loading...
Cat. No.: HY-17569S2
Difluprednate-d3-1 is the deuterium labeled Difluprednate (HY-17569). Difluprednate is a glucocorticoid receptor (GC receptor) agonist with a Ki of 0.78 nM. Difluprednate's active metabolite 21-deacetylated difluprednate (DFB) is a competitive agonist of GC receptors with a Ki of 0.061 nM. Difluprednate binds to GC receptors through metabolism to DFB, regulating the transcription of inflammatory mediator genes, thereby exerting anti-inflammatory activity. Difluprednate can be used for research related to ocular inflammation, such as postoperative inflammation, anterior uveitis, etc .
loading...
    loading...
Cat. No.: HY-180916
CAII-IN-11 (Compound A1) is a dual-target compound that contains a hCA II inhibitor (IC₅₀ = 2 nM) portion and a NO donor portion. CAII-IN-11 also has inhibitory activity against hCA IX, hCA XII, and hCA I, with IC50 values of 6, 3, and 152 nM respectively. CAII-IN-11 significantly increases the intracellular cGMP level in human trabecular meshwork cells. CAII-IN-11 reduces the apoptosis of retinal ganglion cells by reducing oxidative stress (ROS levels), inhibiting astrocytes and the NLRP3 inflammasome activation. CAII-IN-11 has hypotensive activity in rabbit models and can be used for the study of glaucoma .
loading...
    loading...